NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
Clinical Trials
89 trialsNCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT05229601 2025-10-22
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT05582018 2025-09-15
PANORAMA
Techsomed Medical Technologies LTD
Phase NA Terminated
NCT04502082 2025-09-08
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT04989387 2025-09-02
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05451862 2025-08-26
HOMIE-166
Terumo Europe N.V.
Phase NA Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT04520906 2025-07-01
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
Suzhou Hengruihongyuan Medical Technology Co. LTD
Phase NA Terminated
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT05757492 2025-05-01
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Terminated
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT05770882 2025-03-11
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 1/2 Terminated
NCT06848556 2025-02-27
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05909995 2025-02-18
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT01101906 2024-11-20
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Astellas Pharma Inc
Phase 2 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT00687596 2024-09-19
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT02314052 2024-07-11
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Novo Nordisk A/S
Phase 1/2 Terminated
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT04244552 2023-12-29
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
Phase 1 Terminated
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03970616 2023-07-12
DEDUCTIVE
AVEO Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT03591965 2023-07-10
Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
Antengene Corporation
Phase 2 Terminated
NCT04635527 2023-03-16
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT00375011 2022-12-20
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
Meridian Bioscience, Inc.
Terminated
NCT01433016 2022-12-20
OBT for HCC
Meridian Bioscience, Inc.
Phase 2 Terminated
NCT02415036 2022-10-17
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2 Terminated
NCT03998033 2022-08-23
ET-109
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT03655613 2022-05-06
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Apollomics (Australia) Pty. Ltd.
Phase 1/2 Terminated
NCT03316222 2022-05-02
Study of GNS561 in Patients With Liver Cancer
Genoscience Pharma
Phase 1/2 Terminated
NCT02102022 2022-04-25
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Polaris Group
Phase 1/2 Terminated
NCT01387932 2021-11-30
HiQuality
Merit Medical Systems, Inc.
Phase 3 Terminated
NCT03071094 2021-11-19
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Transgene
Phase 1/2 Terminated
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04264754 2021-05-06
Characterization of Methylation Patterns in Hepatocellular Carcinoma
Nucleix Ltd.
Terminated